The US FDA has issued its strongest safety warning for montelukast, highlighting the risk of serious mental health side effects, including suicidal thoughts and behavior.
The US Food and Drug Administration (FDA) has issued its strongest safety warning for montelukast, a medicine widely prescribed for asthma and allergic rhinitis, after receiving reports of serious mental health side effects, including suicidal thoughts and actions. The agency now requires a Boxed Warning on the drug’s prescribing information, urging healthcare professionals to carefully balance its benefits and risks before prescribing, especially for patients with allergic rhinitis. This important safety update aims to help clinicians and patients make more informed treatment decisions while improving awareness of potential neuropsychiatric risks (1✔ ✔Trusted Source
FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis
Go to source
).
The FDA recommends reserving montelukast for allergic rhinitis only when other allergy medicines are ineffective or cannot be tolerated. Patients, caregivers, and healthcare professionals should remain alert for mood or behavioral changes during treatment and seek medical advice promptly if such symptoms occur. Reviewing a patient’s psychiatric history before initiating therapy may also help support informed clinical decision-making.
Advertisement
Why Did the FDA Issue a Boxed Warning for Montelukast?
The FDA strengthened the warning after reviewing reports of neuropsychiatric side effects associated with montelukast. Reported events include:
- Agitation
- Aggressive behavior
- Anxiety
- Depression
- Sleep disturbances
- Hallucinations
- Suicidal thoughts and actions
These reactions have been reported during treatment and, in some patients, after stopping the medicine. The FDA notes that although individual reports do not establish a definite cause-and-effect relationship, the seriousness of these events warranted the addition of its strongest safety warning.
Advertisement
When Should Montelukast Be Prescribed for Asthma or Allergic Rhinitis?
For allergic rhinitis, the FDA recommends prescribing montelukast only for patients who do not respond adequately to or cannot tolerate other available treatments.
For asthma, healthcare professionals should carefully evaluate whether the expected clinical benefits outweigh the potential risk of serious mental health side effects before initiating therapy.
Advertisement
What Should Patients and Healthcare Professionals Watch For?
Patients and caregivers should read the Medication Guide supplied with montelukast and immediately report any new or worsening changes in mood, behavior, or thinking to their healthcare provider. Clinicians should discuss these potential risks before starting treatment and reassess therapy if psychiatric symptoms develop.
Why This FDA Safety Warning Matters
The FDA’s Boxed Warning reinforces the importance of individualized treatment decisions rather than discouraging appropriate use of montelukast. By understanding both the benefits and potential risks of the medicine, patients and healthcare professionals can work together to choose the most appropriate treatment and ensure prompt recognition of any concerning mental health symptoms.
Reference:
- FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis – (https://www.fda.gov/drugs/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug)
Source-Medindia
